Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDC115
- Development stage
- Preclinical
- Lead developer
- Prestige Biopharma Innovative Discovery Centre
- Modality
- Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
IDC115 is a first-in-class therapeutic candidate being developed by Prestige Biopharma IDC. It is currently in the preclinical stage of development for the treatment of solid tumors and immunological disorders. As part of Prestige Biopharma's Innovative Discovery Center (IDC) pipeline, IDC115 represents a novel approach to treating high-unmet-need conditions, although its specific biological target and mechanism of action have not yet been publicly disclosed. The candidate is likely a biologic or antibody-based therapy, consistent with the developer's core focus on innovative antibody discovery and development.
Beyond the preview
Go deeper on IDC115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDC115.